Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:41 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 134 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: In vitro Diagnostic Clear all

Conditions: Multiple Myeloma in Relapse
Interventions: Not listed
Lead sponsor: Travera Inc; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 4
States / cities: Duarte, California • Boston, Massachusetts • New York, New York

Conditions: Infection
Interventions: STD Diagnostic Kit (Identigene); Device
Lead sponsor: Identigene; Industry
Eligibility: 14 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Cancer
Interventions: Ovarian stimulation in vitro fertilization cryopreservation; Procedure
Lead sponsor: New York Medical College; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2018
U.S. locations: 1
States / cities: Valhalla, New York

Conditions: Preeclampsia
Interventions: Not listed
Lead sponsor: Carl Weiner, MD; Other
Eligibility: 16 Years to 45 Years · Female only
Enrollment: 431 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Intra-Amniotic Infection of Foetus
Interventions: Perilynx Analyzer to measure AF and VF fluid; Diagnostic Test
Lead sponsor: Hologic, Inc.; Industry
Eligibility: 18 Years to 50 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 5
States / cities: Long Beach, California • Shreveport, Louisiana • Newark, New Jersey + 2 more

Conditions: Lung Cancer, Technology, Oncology
Interventions: Idylla EGFR Mutation Test; Diagnostic Test
Lead sponsor: Anthony Magliocco; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Urinary Tract Infections
Interventions: Velieve U.S.; Device
Lead sponsor: Healthy.io Ltd.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: West Palm Beach, Florida

Conditions: Cancer
Interventions: protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, biopsy; Genetic · Other · Procedure
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: Up to 120 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Indeterminate Thyroid Cytology
Interventions: In vitro Diagnostic; Diagnostic Test
Lead sponsor: Pontificia Universidad Catolica de Chile; Other
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 6
States / cities: Guntersville, Alabama • Palo Alto, California • Tampa, Florida + 3 more

Conditions: Celiac Disease
Interventions: Not listed
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
Interventions: 3-Dimensional Conformal Radiation Therapy, Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Cisplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide Phosphate, External Beam Radiation Therapy, In Vitro-Treated Peripheral Blood Stem Cell Transplantation, Intensity-Modulated Radiation Therapy, Iobenguane I-131, Isotretinoin, Laboratory Biomarker Analysis, Melphalan, Pharmacological Study, Questionnaire Administration, Therapeutic Conventional Surgery, Topotecan Hydrochloride, Vincristine Sulfate; Radiation · Procedure · Drug + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 30 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2025
U.S. locations: 25
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 20 more

Conditions: Breast Neoplasms, Breast Diseases
Interventions: Not listed
Lead sponsor: Sysmex America, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Tucson, Arizona • Houston, Texas

Conditions: Streptococcus Pyogenes Infection, Pharyngitis, Respiratory Tract Infections
Interventions: untrained lay user performs investigational diagnostic test; Diagnostic Test
Lead sponsor: Checkable Medical Inc; Industry
Eligibility: 5 Years and older
Enrollment: 1,347 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 22
States / cities: Beverly Hills, California • Jacksonville, Florida • Miami, Florida + 18 more

Conditions: Healthy
Interventions: Blood draw; Procedure
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 50 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2029
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hypoplastic Left Heart Syndrome
Interventions: Fetal Aortic Valvuloplasty Procedure, Emerge Monorail and Over-The-Wire PTCA Dilatation Catheter, Trek RX and Mini Trek RX Coronary Dilatation Catheter; Procedure · Device
Lead sponsor: Mauro H. Schenone; Other
Eligibility: Up to 45 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2036
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Coronavirus, Respiratory Infection, COVID
Interventions: Investigational IVD for coronaviruses; Device
Lead sponsor: BioFire Defense LLC; Industry
Eligibility: Not listed
Enrollment: 2,091 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 6
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Tampa, Florida + 3 more

Conditions: Influenza
Interventions: Standard IIV4, Recombinant, Cell-culture; Biological
Lead sponsor: Marshfield Clinic Research Foundation; Other
Eligibility: 18 Years to 64 Years
Enrollment: 366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Marshfield, Wisconsin

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Fiberoptic bronchoscopy, blood draw, intravenous catheter; Procedure
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 80 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Single Gene Disorders
Interventions: Preimplantation Genetic Diagnosis; Other
Lead sponsor: Natera, Inc.; Industry
Eligibility: Not listed
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Redwood City, California

Conditions: Infertility
Interventions: Age; Other
Lead sponsor: Main Line Fertility Center; Other
Eligibility: 21 Years to 42 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Bryn Mawr, Pennsylvania

Conditions: Human T-Lymphotrophic Virus Type I and/or Type II
Interventions: InnoLIA HTLV I/II Score line immunoassay; Device
Lead sponsor: Creative Testing Solutions; Other
Eligibility: Not listed
Enrollment: 3,305 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Abnormal Uterine Bleeding (AUB), Endometrial Cancer, Atypical Endometrial Hyperplasia, Endometrial Hyperplasia With Atypia, Endometrial Intraepithelial Neoplasia
Interventions: Not listed
Lead sponsor: Exact Sciences Corporation; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 4,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 5
States / cities: Sarasota, Florida • Scarborough, Maine • Murfreesboro, Tennessee + 1 more

Conditions: Kidney Failure, Acute, Kidney Failure, Chronic, Blood Platelet Disorders, Hemorrhage
Interventions: measuring Platelet Function Analyser-100 (PFA-100) platelet function before kidney biopsy; Device
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Non-small Cell Lung Cancer, Colorectal Cancer, Breast Cancer
Interventions: Guardant360; Diagnostic Test
Lead sponsor: Guardant Health, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 470 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 1
States / cities: Skokie, Illinois

Search by objective public record fields.

Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma

Identigene STD Test Collection Kit Validation Study

Safety of Ovarian Stimulation With Letrozole and Gonadotropins in Breast Cancer Patients

A Study to Evaluate the Use of Placenta Protein 13 (PP13) in the First Trimester of Pregnancy as a Diagnostic Aiding Tool in the Assessment of the Risk for Developing Preeclampsia in Women With Low and Unknown Risk

Rapid Amniotic Fluid (AF) Test and a Non-Invasive Vaginal Fluid (VF) Test

Idylla EGFR Lung Trial

A Comparative, Controlled Study to Evaluate the Clinical Accuracy of the Velieve U.S. UTI Urine Analysis Test System

OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer

Clinical Validation of ThyroidPrint: A Gene Expression Signature for Diagnosis of Indeterminate Thyroid Nodules

Immune Response in Celiac Disease on In-vitro Gluten Challenge

Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin

Clinical Evaluation of OSNA Breast Cancer System in Breast Cancer Patients Receiving Neoadjuvant Therapy

Clinical Performance of the Checkable Medical At-Home Strep A Test

Lipidomics Screening of Anti-inflammatory Drugs and Drug Candidates in Vitro - Part A

Fetal Aortic Valvuloplasty for Evolving Hypoplastic Left Heart Syndrome

Prospective Clinical Evaluation of the BioFire Emerging Coronavirus Panel for the Detection of COVID-19 and Other Coronaviruses

Randomized Influenza Vaccine Evaluation of Immune Response

Apoptotic Cell (AC) Uptake by Human Alveolar Macrophages (AM)

Clinical Use of Parental Support To Detect Single Gene Mutations

Mitochondrial Activity of Cumulus Cells From the Cumulus-oocyte Complex and Oocyte Competence

Evaluation of InnoLIA HTLV I/II Score

Endometrial Cancer Vaginal Fluid Specimen Collection Study

Does An Abnormal PFA 100 Predict Bleeding After Renal Biopsy?

SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation